Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
Emergent BioSolutions (NYSE:EBS) has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International for $36.5 million, subject to post-closing adjustments. The transaction includes the transfer of facility assets and equipment to Syngene.
As part of the agreement, Emergent maintains rights to access manufacturing services and capacity at the facility for future growth and pandemic response production in partnership with Syngene. The company's CEO Joe Papa stated this strategic move aligns with their multi-year transformation efforts to streamline operations while maintaining production flexibility.
Emergent BioSolutions (NYSE:EBS) ha completato la vendita del suo stabilimento di produzione di principi attivi a Baltimore-Bayview a Syngene International per 36,5 milioni di dollari, soggetto ad aggiustamenti post-chiusura. La transazione include il trasferimento degli asset e delle attrezzature dello stabilimento a Syngene.
Come parte dell'accordo, Emergent mantiene i diritti di accesso ai servizi di produzione e alla capacità dello stabilimento per la crescita futura e la produzione in risposta a pandemie in partnership con Syngene. Il CEO dell'azienda, Joe Papa, ha dichiarato che questa mossa strategica è in linea con i loro sforzi di trasformazione pluriennali per semplificare le operazioni mantenendo la flessibilità produttiva.
Emergent BioSolutions (NYSE:EBS) ha completado la venta de su instalación de fabricación de sustancias farmacéuticas en Baltimore-Bayview a Syngene International por 36,5 millones de dólares, sujeta a ajustes posteriores al cierre. La transacción incluye la transferencia de activos e instalaciones a Syngene.
Como parte del acuerdo, Emergent mantiene derechos de acceso a los servicios de fabricación y capacidad en la instalación para el crecimiento futuro y la producción en respuesta a pandemias en colaboración con Syngene. El CEO de la empresa, Joe Papa, declaró que este movimiento estratégico se alinea con sus esfuerzos de transformación a largo plazo para optimizar las operaciones mientras se mantiene la flexibilidad en la producción.
Emergent BioSolutions (NYSE:EBS)는 볼티모어-베이뷰의 의약품 원료 제조 시설을 Syngene International에 3650만 달러에 매각하는 거래를 완료했습니다. 이 거래는 Syngene에 시설 자산과 장비를 이전하는 내용을 포함합니다.
합의의 일환으로 Emergent는 Syngene과의 파트너십을 통해 향후 성장 및 팬데믹 대응 생산을 위한 제조 서비스 및 시설 접근 권한을 유지합니다. 회사의 CEO인 Joe Papa는 이 전략적 조치가 운영 간소화와 생산 유연성 유지를 위한 다년 간의 변혁 노력과 일치한다고 밝혔습니다.
Emergent BioSolutions (NYSE:EBS) a finalisé la vente de son installation de fabrication de substances médicamenteuses à Baltimore-Bayview à Syngene International pour 36,5 millions de dollars, sous réserve d'ajustements postérieurs à la clôture. La transaction comprend le transfert des actifs et de l'équipement de l'installation à Syngene.
Dans le cadre de l'accord, Emergent conserve des droits d'accès aux services de fabrication et à la capacité de l'installation pour la croissance future et la production en réponse aux pandémies en partenariat avec Syngene. Le PDG de l'entreprise, Joe Papa, a déclaré que ce mouvement stratégique s'aligne avec leurs efforts de transformation pluriannuels pour rationaliser les opérations tout en maintenant la flexibilité de production.
Emergent BioSolutions (NYSE:EBS) hat den Verkauf seiner Wirkstoffproduktionsanlage in Baltimore-Bayview an Syngene International für 36,5 Millionen Dollar abgeschlossen, vorbehaltlich nachträglicher Anpassungen. Die Transaktion umfasst die Übertragung von Anlagen und Ausrüstungen an Syngene.
Im Rahmen des Vertrags behält Emergent die Rechte auf Zugang zu Fertigungsdienstleistungen und Kapazitäten in der Anlage für zukünftiges Wachstum und die Produktion zur Pandemiebewältigung in Partnerschaft mit Syngene. Der CEO des Unternehmens, Joe Papa, erklärte, dass dieser strategische Schritt mit ihren mehrjährigen Transformationsbemühungen zur Optimierung der Abläufe und zur Aufrechterhaltung der Produktionsflexibilität in Einklang steht.
- Received $36.5 million in immediate cash proceeds
- Retained manufacturing rights for future production needs
- Strategic alignment with operational streamlining initiatives
- Divestment of major manufacturing asset
GAITHERSBURG, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International. Emergent received approximately
Pursuant to the sale, Syngene acquired the assets and equipment associated with the Baltimore-Bayview facility. In addition, Emergent retains the rights to secure manufacturing services and capacity at the facility for future growth and pandemic response production in collaboration with Syngene.
“This deal enables us to streamline operations, while maintaining flexibility for future product demand.” said Joe Papa, president and CEO of Emergent. “As we continue our multi-year transformation, we are well positioned to execute on our turnaround initiatives and drive sustainable, long-term growth.”
For Emergent, Truist served as financial advisor, and Covington & Burling LLP served as legal counsel in connection with this transaction.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding Emergent’s ability to achieve the objectives of the disposition of its Baltimore-Bayview facility, including achieving improvement in performance by streamlining Emergent’s manufacturing network, and Emergent’s future results, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “improve,” “intend,” “may,” “plan,” “position,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statements will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause Emergent’s actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors and other disclosures included in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
FAQ
How much did Emergent BioSolutions (EBS) receive for the Baltimore-Bayview facility sale?
Will EBS retain any manufacturing rights at the Baltimore-Bayview facility after the sale?
Who were the advisors for EBS in the Baltimore-Bayview facility sale?
What assets did Syngene International acquire in the EBS facility purchase?
